Altamira TherapeuticsCYTOF -21.72% EV-to-FCF is -0.25 as of Jul. 12, 2026. The stock has 4 warning signs investors should review. Among 329 Biotechnology companies, Altamira Therapeutics ranks worse than 303951.06% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Altamira Therapeutics's Enterprise Value is $1.07 Mil.
Altamira Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was $-4.29 Mil. Therefore, Altamira Therapeutics's EV-to-FCF for today is -0.25.
The historical rank and industry rank for Altamira Therapeutics's EV-to-FCF or its related term are showing as below:
CYTOF'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.25 Med: 0 Max: 0
Current: -0.25
CYTOF's EV-to-FCF is ranked worse than 100% of 329
companies
in the Biotechnology industry
Industry Median: 15.85
vs CYTOF: -0.25
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Altamira Therapeutics's PE Ratio (TTM) for today is calculated as:
Altamira Therapeutics's share price for today is $0.0501.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was $-1.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Altamira Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Altamira Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Altamira Therapeutics's EV-to-FCF falls into.
Altamira Therapeutics's current Enterprise Value is $1.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was $-4.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Altamira Therapeutics (CYTOF) has a EV-to-FCF of -0.25 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Altamira Therapeutics and its competitors. According to the industry distribution chart, Altamira Therapeutics ranks #999999 out of 329 companies in the Biotechnology industry.
Is Altamira Therapeutics' EV-to-FCF too high?
Altamira Therapeutics' current EV-to-FCF is -0.25. Based on the distribution chart, Altamira Therapeutics ranks #999999 out of 329 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Altamira Therapeutics' EV-to-FCF compare to IOBTQ and SCPX?
According to the Biotechnology industry distribution chart, Altamira Therapeutics ranks #999999 out of 329 companies for EV-to-FCF. This places Altamira Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 15.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.85, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Altamira Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Altamira Therapeutics's current EV-to-FCF is -0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (CYTOF) has a current EV-to-FCF of -0.25. The current EV-to-FCF is -0.25. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Altamira Therapeutics (CYTOF), the current EV-to-FCF is -0.25 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CYTOF has been successfully added to your 